Plans Advancing for Trial of Elamipretide in Aiding Cardiac Muscle in DMD

Plans Advancing for Trial of Elamipretide in Aiding Cardiac Muscle in DMD

314773

Plans Advancing for Trial of Elamipretide in Aiding Cardiac Muscle in DMD

A branch of the U.S. Food and Drug Administration (FDA) known as the Division of Cardiology and Nephrology has given positive feedback to Stealth BioTherapeutics‘ program for Duchenne muscular dystrophy (DMD). In a pre-investigational new drug (pre-IND) meeting, the division — called the DCN — agreed to the design of a proposed clinical trial assessing elamipretide, which aims to increase the activity of mitochondria and treat cardiac muscle disease in Duchenne. Mitochondria are the cell structures responsible…

You must be logged in to read/download the full post.